Creative Planning Intercept Pharmaceuticals, Inc. Transaction History

Creative Planning

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Jan 30, 2020	SELL	$57.36 - $124.1 $625,510 - $1.35 Million	-10,905 Closed	0 $0
Q3 2019 Nov 01, 2019	BUY	$58.69 - $80.46 $640,014 - $877,416	10,905 New	10,905 $724,000
Q2 2019 Jul 26, 2019	SELL	$77.77 - $120.68 $2.58 Million - $4 Million	-33,175 Closed	0 $0
Q1 2019 Apr 24, 2019	BUY	$91.83 - $120.68 $3.05 Million - $4 Million	33,175 New	33,175 $3.71 Million
Q4 2018 Feb 01, 2019	SELL	$85.79 - $126.46 $231,633 - $341,442	-2,700 Closed	0 $0
Q3 2018 Oct 25, 2018	SELL	$88.49 - $127.55 $92,029 - $132,652	-1,040 Reduced 27.81%	2,700 $341,000
Q2 2018 Jul 20, 2018	BUY	$60.0 - $85.67 $224,400 - $320,405	3,740 New	3,740 $314,000
Q4 2017 Jan 17, 2018	SELL	$58.2 - $72.76 $571,524 - $714,503	-9,820 Closed	0 $0
Q3 2017 Oct 17, 2017	BUY	$57.01 - $118.75 $559,838 - $1.17 Million	9,820	9,820 $570,000

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

Stay updated on Creative Planning with notifications on news.